Trial Profile
BIOTRONIK-Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in the Treatment of Patients With Single de Novo Coronary Artery Lesions in an Indian Population.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms BIOFLOW-INDIA
- Sponsors BIOTRONIK
- 23 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Sep 2011 New trial record